Transferrin-Conjugated Nanocarriers as Active-Targeted Drug Delivery Platforms for Cancer Therapy

Title:Transferrin-Conjugated Nanocarriers as Active-Targeted Drug Delivery Platforms for Cancer Therapy

Volume: 23 Issue: 3

Author(s): Daniele R. Nogueira-Librelotto, Cristiane F. Codevilla, Ammad Farooqi and Clarice M. B. Rolim

Affiliation:

Keywords: Active-targeted drug delivery, nanocarriers, transferrin, tumor cells, cancer therapy.

Abstract: A lot of effort has been devoted to achieving active targeting for cancer therapy in order to reach the right cells. Hence, increasingly it is being realized that active-targeted nanocarriers notably reduce off-target effects, mainly because of targeted localization in tumors and active cellular uptake. In this context, by taking advantage of the overexpression of transferrin receptors on the surface of tumor cells, transferrin-conjugated nanodevices have been designed, in hope that the biomarker grafting would help to maximize the therapeutic benefit and to minimize the side effects. Notably, active targeting nanoparticles have shown improved therapeutic performances in different tumor models as compared to their passive targeting counterparts. In this review, current development of nano-based devices conjugated with transferrin for active tumor-targeting drug delivery are highlighted and discussed. The main objective of this review is to provide a summary of the vast types of nanomaterials that have been used to deliver different chemotherapeutics into tumor cells, and to ultimately evaluate the progression on the strategies for cancer therapy in view of the future research.

Cite this article as:

Nogueira-Librelotto R. Daniele, Codevilla F. Cristiane, Farooqi Ammad and Rolim M. B. Clarice, Transferrin-Conjugated Nanocarriers as Active-Targeted Drug Delivery Platforms for Cancer Therapy, Current Pharmaceutical Design 2017; 23 (3) . https://dx.doi.org/10.2174/1381612822666161026162347